Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma 2Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

X-Rays 4Phantoms, Imaging 4Specimen Handling 3Magnetic Resonance Spectroscopy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2ivosidenib 2Vemurafenib 2Triptorelin Pamoate 2Nuclear Medicine Department, Hospital 2LY3023414 2Drug Therapy 2surufatinib 1olaparib 1larotrectinib 1fludarabine 1erdafitinib 1ensartinib 1copanlisib 1bempegaldesleukin 1Zoledronic Acid 1Stem Cell Transplantation 1Sirolimus 1Proton Therapy 1Pharmacogenomic Variants 1Nivolumab 1Methionine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × BAY 1895344 × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡